Tiesha Panek
Psychiatry · Cary, ILNPI 1477250595
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 251 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,303 and has fallen 51.4% since, to $1,120 in 2025. Among psychiatry clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 251 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lundbeck LLC$419
- Otsuka America Pharmaceutical, Inc.$402
- Alkermes, Inc.$385
- Corium, LLC$332
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$300
- plus $2K from 20 others
What the payments were for
- Food & beverage$4,931100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 87 | $1,178 |
| Lundbeck LLC | 25 | $419 |
| Otsuka America Pharmaceutical, Inc. | 18 | $402 |
| Alkermes, Inc. | 14 | $385 |
| Corium, LLC | 15 | $332 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $300 |
| Harmony Biosciences LLC | 11 | $281 |
| Neurocrine Biosciences, Inc. | 8 | $235 |
| Teva Pharmaceuticals USA, Inc. | 9 | $198 |
| Axsome Therapeutics, Inc. | 6 | $189 |
| Pfizer | 8 | $168 |
| Tris Pharma Inc | 7 | $138 |
| Supernus Pharmaceuticals, Inc. | 6 | $122 |
| Ironshore Pharmaceuticals Inc. | 4 | $89 |
| E.r. Squibb & Sons, L.L.C. | 3 | $81 |
| Neos Therapeutics, LP | 4 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $76 |
| Bausch Health US, LLC | 2 | $42 |
| Jazz Pharmaceuticals Inc. | 1 | $39 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Johnson & Johnson | 1 | $29 |
| UCB, Inc. | 1 | $29 |
| Impel Pharmaceuticals Inc. | 1 | $24 |
| Tempus AI, Inc | 1 | $23 |
| OWP Pharmaceuticals, Inc. | 1 | $20 |
| Upsher-smith Laboratories LLC | 1 | $19 |
How this compares
$4,931 in reported general payments places this provider in the 90th percentile of 1,344 psychiatry providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 16 | $37,719 |
| Olanzapine | 33 | $7,927 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 23 | $553 |
| Hydroxyzine Hcl | 11 | $509 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 14 | $501 |
| Duloxetine Hcl | 25 | $491 |
| Clonazepam | 53 | $352 |
| Quetiapine Fumarate | 22 | $320 |
| Escitalopram Oxalate | 36 | $314 |
| Lamotrigine | 22 | $272 |
| Memantine Hcl | 11 | $261 |
| Fluoxetine Hcl | 18 | $205 |
| Alprazolam | 40 | $187 |
| Diazepam | 14 | $171 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 12 | $142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,178 | $37,71916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Cary
- Michael FeldNorthbrook$1.1M
- Jose MontesRockford$882K
- Mitchell GlaserChicago$752K
- Roukan JazayerliOrland Park$597K
- Ming XuBourbonnais$505K
- Peter WeidenChicago$440K
- Michelle DeesChicago$289K
- Mark ShukhmanSkokie$250K
- Abid NazeerOak Brook$228K
- Nitin ThaparOrland Park$216K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.